CAR-T Therapy market is projected to grow at a CAGR of 35.9% by 2034: Visiongain [Yahoo! Finance]
Bristol-Myers Squibb Company (BMY)
Last bristol-myers squibb company earnings: 2/6 07:05 am
Check Earnings Report
US:NYSE Investor Relations:
bms.com/investors.html
Company Research
Source: Yahoo! Finance
Lymphoblastic Leukaemia (ALL), Follicular Lymphoma, Multiple Myeloma (MM), Others), by Type (Abecma, Yescarta, Kymriah, Tecartus, Others), by Target Antigens (CD19/CD22, BCMA, Others), by Patient (Children, Adults, Seniors), by End-users (Hospitals, Specialty Clinics, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies The global CAR-T Therapy market is estimated at US$1,482.2 million in 2024 and is projected to grow at a CAGR of 35.9% during the forecast period 2024-2034. Increasing Research and Development to Enhance Treatment with CAR-T Cell Therapy Scientists are always coming up with new ways to make CAR T-cells that are more successful at fighting a larger variety of malignancies, including solid tumours for which CAR T-cell therapy is still being investigated. Research is still being done to address some of the drawbacks of CAR T-cell treatment, including high costs, limited persistence, and possible adverse effects. Research and d
Show less
Read more
Impact Snapshot
Event Time:
BMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMY alerts
High impacting Bristol-Myers Squibb Company news events
Weekly update
A roundup of the hottest topics
BMY
News
- Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)Business Wire
- Global Healthy Living Foundation Announces Groundbreaking Survey Revealing Significant Health Disparities Among LGBTQ+ Individuals Living with Inflammatory Bowel Disease [Yahoo! Finance]Yahoo! Finance
- European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab [Yahoo! Finance]Yahoo! Finance
- European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous NivolumabBusiness Wire
BMY
Earnings
- 4/25/24 - Miss
BMY
Sec Filings
- 6/18/24 - Form 8-K
- 5/9/24 - Form 8-K
- 5/3/24 - Form 4
- BMY's page on the SEC website